Kymera Therapeutics, Inc. (KYMR) has a consensus analyst rating of Buy, based on 26 analysts covering the stock. Of those, 23 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for KYMR is $117.31, representing a +30.5% upside from the current price of $89.865. Price targets range from a low of $90.00 to a high of $138.00.
